Daré Bioscience posts new investor presentation

Q: What did Daré Bioscience (DARE) announce in this Form 8-K?

Daré Bioscience furnished a corporate presentation dated September 9, 2026 as Exhibit 99.1 under a Regulation FD disclosure for use in meetings with securities market participants and others.

Q: How will Daré Bioscience (DARE) use the September 9, 2026 presentation?

The company intends to use the September 9, 2026 corporate presentation in various meetings with securities market participants and others, commencing on that same date.

Q: Where can investors access Daré Bioscience’s September 9, 2026 presentation?

Daré plans to post the September 9, 2026 corporate presentation in the Investors section of its website, on the “Presentations, Events & Webcasts” page under the heading “Presentations.”

Q: Is the Daré Bioscience (DARE) presentation considered filed with the SEC?

No. The information in Item 7.01 and Exhibit 99.1 is being furnished and is not deemed “filed” under Section 18 of the Exchange Act or incorporated into other SEC filings, unless specifically referenced.

Q: What exhibits are included in this Daré Bioscience (DARE) Form 8-K?

The Form 8-K lists Exhibit 99.1, Daré Bioscience corporate presentation dated September 9, 2026, and Exhibit 104, the Cover Page Interactive Data File embedded within the Inline XBRL document.

Daré Bioscience is furnishing, but not filing, an investor presentation dated September 9, 2026 for use with market participants and on its website.

Filing Impact

(High)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Daré Bioscience, Inc. (DARE) furnished a corporate presentation as an exhibit to a current report under a Regulation FD disclosure. The presentation is dated September 9, 2026 and may be used in meetings with securities market participants and others starting on that date.

The presentation will also be made available in the Investors section of Daré’s website under “Presentations, Events & Webcasts.” The furnished materials, including Exhibit 99.1, are not deemed filed for purposes of Section 18 of the Exchange Act or incorporated by reference into other securities filings, except if specifically referenced.

Insights

Analyzing...

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Terms

Regulation FD Disclosure, Emerging growth company, Inline XBRL

3 terms

Regulation FD Disclosure regulatory

"Item 7.01 Regulation FD Disclosure."

Regulation FD disclosure requires public companies to share important, market-moving information with everyone at the same time instead of tipping off analysts or large investors first. Think of it as making sure all players on a field hear the same announcement simultaneously; that fairness helps investors trust that stock prices reflect the same information and reduces the risk of sudden, unfair trading advantages or regulatory penalties for selective leaks.

Emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Inline XBRL technical

"Cover Page Interactive Data File (embedded within the Inline XBRL document)"

Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.

FAQ

What did Daré Bioscience (DARE) announce in this Form 8-K?

Daré Bioscience furnished a corporate presentation dated September 9, 2026 as Exhibit 99.1 under a Regulation FD disclosure for use in meetings with securities market participants and others.

How will Daré Bioscience (DARE) use the September 9, 2026 presentation?

The company intends to use the September 9, 2026 corporate presentation in various meetings with securities market participants and others, commencing on that same date.

Where can investors access Daré Bioscience’s September 9, 2026 presentation?

Daré plans to post the September 9, 2026 corporate presentation in the Investors section of its website, on the “Presentations, Events & Webcasts” page under the heading “Presentations.”

Is the Daré Bioscience (DARE) presentation considered filed with the SEC?

No. The information in Item 7.01 and Exhibit 99.1 is being furnished and is not deemed “filed” under Section 18 of the Exchange Act or incorporated into other SEC filings, unless specifically referenced.

What exhibits are included in this Daré Bioscience (DARE) Form 8-K?

The Form 8-K lists Exhibit 99.1, Daré Bioscience corporate presentation dated September 9, 2026, and Exhibit 104, the Cover Page Interactive Data File embedded within the Inline XBRL document.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 09/09/2026 - 09:01 AM Accepted by SEC EDGAR 09/09/2026 - 09:00 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 9, 2026

DARE BIOSCIENCE, INC.

DARÉ BIOSCIENCE, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-36395

20-4139823

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

3655 Nobel Drive, Suite 260

San Diego, CA 92122

(Address of Principal Executive Offices and Zip Code)

Registrant’s telephone number, including area code: (858) 926-7655

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock		DARE		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

Furnished as Exhibit 99.1 to this report is a copy of a corporate presentation of Daré Bioscience, Inc. (“Daré” or the “Company”) dated September 9, 2026, which is incorporated herein by reference. The Company intends to use the presentation and its contents in various meetings with securities market participants and others, commencing on September 9, 2026.

The Company plans to make a copy of the presentation available in the “Investors” section of its website (https://ir.darebioscience.com), on the page titled “Presentations, Events & Webcasts,” under the heading “Presentations.” Information contained in, or that can be accessed through, the Company’s website or any other website referenced in the presentation is not incorporated by reference into this report.

The information in this Item 7.01 and Exhibit 99.1 to this report is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation by reference language in any such filing, except as the Company expressly sets forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d)

Exhibits.

Exhibit No.		Description
99.1		Daré Bioscience corporate presentation, dated September 9, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	DARÉ BIOSCIENCE, INC.

Dated: September 9, 2026	By:	/s/ Sabrina Martucci Johnson
	Name:	Sabrina Martucci Johnson
	Title:	President and Chief Executive Officer